S&P 500   3,211.97 (-0.45%)
DOW   26,705.09 (-0.61%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
S&P 500   3,211.97 (-0.45%)
DOW   26,705.09 (-0.61%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
S&P 500   3,211.97 (-0.45%)
DOW   26,705.09 (-0.61%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
S&P 500   3,211.97 (-0.45%)
DOW   26,705.09 (-0.61%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
Log in

NASDAQ:VTGNVistagen Therapeutics News Headlines

$0.59
+0.01 (+2.41 %)
(As of 07/16/2020 02:08 PM ET)
Add
Compare
Today's Range
$0.58
Now: $0.59
$0.61
50-Day Range
$0.43
MA: $0.51
$0.61
52-Week Range
$0.29
Now: $0.59
$1.49
Volume28,625 shs
Average Volume1.13 million shs
Market Capitalization$33.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33

Headlines

Vistagen Therapeutics (NASDAQ VTGN) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to Post -$0.10 EPSZacks: Analysts Expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to Post -$0.10 EPS
www.americanbankingnews.com - July 12 at 7:08 PM
Vistagen Therapeutics (NASDAQ:VTGN) Announces  Earnings Results, Beats Expectations By $0.01 EPSVistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - June 30 at 7:07 AM
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline UpdateVistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
finance.yahoo.com - June 29 at 7:21 PM
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million DealWeek In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
seekingalpha.com - June 28 at 1:29 PM
Vistagen Therapeutics (NASDAQ:VTGN) Rating Reiterated by Maxim GroupVistagen Therapeutics (NASDAQ:VTGN) Rating Reiterated by Maxim Group
www.americanbankingnews.com - June 26 at 2:23 PM
VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast AsiaVistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
finance.yahoo.com - June 25 at 9:10 AM
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS ConditionsVistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
www.prnewswire.com - May 27 at 9:12 AM
VistaGen submits guidelines for Phase 2A study of PH94BVistaGen submits guidelines for Phase 2A study of PH94B
seekingalpha.com - May 18 at 10:36 AM
VistaGen Submits PH94B Phase 2A Study Protocol To FDA - Quick FactsVistaGen Submits PH94B Phase 2A Study Protocol To FDA - Quick Facts
www.nasdaq.com - May 18 at 10:36 AM
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
finance.yahoo.com - May 18 at 10:36 AM
VistaGen Therapeutics (NASDAQ:VTGN) Is Arguably In A Tricky SituationVistaGen Therapeutics (NASDAQ:VTGN) Is Arguably In A Tricky Situation
finance.yahoo.com - April 29 at 11:33 AM
Health-Care Stocks Leap on Exciting NewsHealth-Care Stocks Leap on Exciting News
www.baystreet.ca - April 28 at 4:04 PM
VistaGen up 7% on foray into COVID-19VistaGen up 7% on foray into COVID-19
seekingalpha.com - April 28 at 11:04 AM
VistaGen +26% premarket on expanded use of PH94BVistaGen +26% premarket on expanded use of PH94B
seekingalpha.com - April 28 at 11:04 AM
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
finance.yahoo.com - April 28 at 11:04 AM
VistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarketVistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarket
seekingalpha.com - March 25 at 1:04 PM
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 MillionVistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
finance.yahoo.com - March 25 at 1:04 PM
VistaGen up 15% premarket on positive PH10 dataVistaGen up 15% premarket on positive PH10 data
seekingalpha.com - February 20 at 12:55 PM
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive DisorderVistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
finance.yahoo.com - February 20 at 12:55 PM
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline OverviewVistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
finance.yahoo.com - February 13 at 7:15 PM
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration EffectsVistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
finance.yahoo.com - February 11 at 3:03 PM
VistaGen on go with mid-stage study of AV-101 in Parkinsons; shares up 8%VistaGen on go with mid-stage study of AV-101 in Parkinson's; shares up 8%
seekingalpha.com - January 30 at 2:42 PM
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease PatientsVistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
finance.yahoo.com - January 30 at 9:40 AM
VistaGen +19% premarket on positive AV-101 resultsVistaGen +19% premarket on positive AV-101 results
seekingalpha.com - December 19 at 2:26 PM
VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in VeteransVistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans
finance.yahoo.com - December 19 at 9:00 AM
NetworkNewsBreaks - VistaGen Therapeutics, Inc.s VTGN PH94B Receives FDA Fast Track Designation to Treat Social Anxiety DisorderNetworkNewsBreaks - VistaGen Therapeutics, Inc.'s VTGN PH94B Receives FDA Fast Track Designation to Treat Social Anxiety Disorder
www.marketwatch.com - December 10 at 5:35 PM
VistaGen Fast-Tracked by FDA for SAD TreatmentVistaGen Fast-Tracked by FDA for SAD Treatment
www.baystreet.ca - December 10 at 12:34 PM
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety DisorderU.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
finance.yahoo.com - December 10 at 12:34 PM
VistaGen Therapeutics Inc.VistaGen Therapeutics Inc.
www.barrons.com - November 20 at 10:21 PM
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & MoreBiotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
finance.yahoo.com - November 20 at 12:20 PM
VistaGen's (VTGN) Major Depressive Disorder Drug DisappointsVistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
finance.yahoo.com - November 15 at 10:57 AM
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive DisorderVistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
finance.yahoo.com - November 14 at 9:53 AM
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline OverviewVistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
finance.yahoo.com - November 7 at 7:41 AM
VistaGen Therapeutics: PH10s Approval Potential Just Cant Outweigh Stock Dilution RiskVistaGen Therapeutics: PH10's Approval Potential Just Can't Outweigh Stock Dilution Risk
seekingalpha.com - November 5 at 12:50 PM
Were A Little Worried About VistaGen Therapeuticss (NASDAQ:VTGN) Cash Burn RateWe're A Little Worried About VistaGen Therapeutics's (NASDAQ:VTGN) Cash Burn Rate
finance.yahoo.com - November 1 at 7:15 PM
We're A Little Worried About VistaGen Therapeutics's (NASDAQ:VTGN) Cash Burn RateWe're A Little Worried About VistaGen Therapeutics's (NASDAQ:VTGN) Cash Burn Rate
finance.yahoo.com - November 1 at 2:14 PM
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinsons DiseaseVistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
finance.yahoo.com - October 28 at 8:55 AM
Blair likes VistaGen in premarket analyst actionBlair likes VistaGen in premarket analyst action
seekingalpha.com - August 28 at 12:01 PM
VistaGen completes enrollment in mid-stage AV-101 study; shares up 10%VistaGen completes enrollment in mid-stage AV-101 study; shares up 10%
seekingalpha.com - August 15 at 11:16 AM
VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive DisorderVistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
finance.yahoo.com - August 15 at 11:16 AM
VistaGen Therapeutics, Inc.: VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial ResultsVistaGen Therapeutics, Inc.: VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
www.finanznachrichten.de - August 13 at 11:47 PM
VistaGen Therapeutics EPS misses by $0.04VistaGen Therapeutics EPS misses by $0.04
seekingalpha.com - August 13 at 11:47 PM
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial ResultsVistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
finance.yahoo.com - August 13 at 11:47 PM
VistaGen nabs U.S. patent covering PH10 for MDD; shares up 6%VistaGen nabs U.S. patent covering PH10 for MDD; shares up 6%
seekingalpha.com - July 24 at 9:00 AM
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal SprayVistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
finance.yahoo.com - July 23 at 9:05 AM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?
finance.yahoo.com - June 27 at 8:35 AM
VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline OverviewVistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview
finance.yahoo.com - June 25 at 7:30 PM
VistaGen Announces Positive Preclinical Data Supporting AV-101s Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinsons Disease, Without The Psychological Side Effects And Safety Concerns Of AmantadineVistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine
finance.yahoo.com - June 20 at 7:50 PM
VistaGen Announces Positive Preclinical Data Supporting AV-101s Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side EffectsVistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects
finance.yahoo.com - May 30 at 6:41 PM
VistaGen Therapeutics, Inc.: VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, ChinaVistaGen Therapeutics, Inc.: VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China
www.finanznachrichten.de - May 7 at 6:59 PM
This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.